Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine

Olin, Patrick; Gustafsson, Lennart; Barreto, Luis; Hessel, Luc; Mast, T. Christopher; Rie, Annelies Van; Bogaerts, Hugues; Storsæter, Jann

doi:10.1016/s0264-410x(02)00777-6

Cited by 108 publications

(73 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One contentious interpretation of that study is that vaccine components may be responsible for a portion of the increased prevalence of asthma and allergies in U.S. children. However, a large number of previous studies have demonstrated that Pa protects against the devastating and sometimes fatal childhood disease whooping cough (27,44,50,54) and that current commercial formulations of Pa show greatly reduced reactogenicities compared to that of Pw (6). The latter data unequivocally demonstrate the benefit of Pa immunization to health and justify the selection of Pa for mass vaccination protocols.…”

Section: Discussionmentioning

confidence: 93%

Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due toBordetella pertussisin a Murine Model

Ennis

Cassidy

Mahon

2005

Clin Vaccine Immunol

View full text Add to dashboard Cite

The prevalence of asthma and allergic disease has increased in many countries, and there has been speculation that immunization promotes allergic sensitization. Bordetella pertussis infection exacerbates allergic asthmatic responses. We investigated whether acellular pertussis vaccine (Pa) enhanced or prevented B. pertussis-induced exacerbation of allergic asthma. Groups of mice were immunized with Pa, infected with B. pertussis, and/or sensitized to ovalbumin. Immunological, pathological, and physiological changes were measured to assess the impact of immunization on immune deviation and airway function. We demonstrate that immunization did not enhance ovalbumin-specific serum immunoglobulin E production. Histopathological examination revealed that immunization reduced the severity of airway pathology associated with sensitization in the context of infection and decreased bronchial hyperreactivity upon methacholine exposure of infected and sensitized mice. These data demonstrate unequivocally the benefit of Pa immunization to health and justify selection of Pa in mass vaccination protocols. In the absence of infection, the Pa used in this study enhanced the interleukin-10 (IL-10) and IL-13 responses and influenced airway hyperresponsiveness to sensitizing antigen; however, these data do not suggest that Pa contributes to childhood asthma overall. On the contrary, wild-type virulent B. pertussis is still circulating in most countries, and our data suggest that the major influence of Pa is to protect against the powerful exacerbation of asthma-like pathology induced by B. pertussis.

show abstract

Section: Discussionmentioning

confidence: 93%

Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due toBordetella pertussisin a Murine Model

Ennis

Cassidy

Mahon

2005

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Also, several other observational studies [17][18][19] have demonstrated a decrease in B. pertussis incidence rates in unvaccinated subgroups (when the vaccination uptake was higher than 80%). Furthermore, a decrease in the transmission of B. pertussis infection from vaccinated through household contacts was observed in several vaccine efficacy studies [20][21][22][23].…”

Section: Discussionmentioning

confidence: 94%

Cost-effectiveness of pertussis booster vaccination in the Netherlands

Rozenbaum¹,

Cao²,

Postma³

2012

Vaccine

View full text Add to dashboard Cite

a b s t r a c tThe aim of the current study is to estimate the epidemiological and economical consequences of several extended pertussis booster vaccination strategies and to explore the impact of parameters surrounded by large uncertainty on the cost-effectiveness.We developed an age structured transmission dynamic model to evaluate the impact of programs targeting (i) adolescents or adults using a single booster dose, (ii) a combination of adolescent and adult vaccination, and (iii) an every 10 years booster dose.The base case analysis, that is a single adolescent booster administered at the age of 12 years, resulted in a reduction of pertussis infections. However, due to an increase in the number of symptomatic infections in adults, the benefits in terms of QALYs gained and costs saved in children were partly offset. Despite these negative indirect effects in the adult population, administering an additional booster dose could still be considered cost effective with an ICER of D 4200 per QALY gained. Combining an adolescent booster dose at the age of 10 (most cost-effective age for a single adolescent booster dose) with an adult (18-30 years) booster dose always resulted in favorable ICERs (

show abstract

“…[11][12][13][14][15][16][17] Changes in the pertussis vaccination schedule in Catalonia occurred during the study period, similar to those occurring in other countries, such as Sweden, Italy and Finland. [18][19][20][21] These changes and changes introduced in the pertussis surveillance system in Catalonia make it difficult to interpret the data.…”

Section: Discussionmentioning

confidence: 99%

“…18 In Sweden, a study performed after the introduction of DTaP in 1996 found a decrease in pertussis incidence in children under school age and a reduction in the hospitalization rate. 19 The study ended in 2000, three years after the introduction of DTaP and the results were, at first, inspiring. However, Sweden was in an unusual situation with respect to pertussis vaccination: DTwP was withdrawn in 1979 and there had been no pertussis vaccination until the inclusion of DTaP in 1996.…”

Section: Discussionmentioning

confidence: 99%